Please assess the completion status of the following clinical trial:

Trial Title: Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum urate level:~  * \>= 7.0mg/dL in patients with gouty nodule or with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL~* Disease type in the classification of hyperuricemia: Uric acid-underexcretion type or mixed type~* Outpatients~Exclusion Criteria:~* Gouty arthritis within 14 days before randomized allocation~* Secondary hyperuricemia~* HbA1c: \>= 8.4%~* Clinically significant cardiac, hepatic, renal, hematologic or endocrine disease~* Kidney calculi or clinically significant urinary calculi~* AST: \>= 100 IU/L or ALT: \>= 100 IU/L~* eGFR: \< 30 mL/min/1.73m\^2~* Systolic blood pressure: \>= 180 mmHg or diastolic blood pressure: \>= 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FYU-981 (Type: EXPERIMENTAL): None
- Febuxostat (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).